McKesson stock rises 3.9% on a CVS extension to 2032; CVS was 24% of its $403 billion in sales

McKesson said on Thursday it has signed an agreement in principle to keep distributing pharmaceuticals to CVS Health through June 2032, covering CVS's mail order and specialty pharmacies, its retail stores and its distribution centers. The company reaffirmed its fiscal 2027 guidance for adjusted earnings of $44.20 to $45.00 a share, according to its press release carried on Business Wire.

McKesson shares were up 3.9% at about $887 at 10:54 a.m. ET, according to Nasdaq quotes, after trading as high as $924.21, about 8% above Wednesday's close. CVS was down about 1% at $84.79. Investing.com also reported the rise.

The number behind the number: one customer, about $97 billion

The press release does not say how big the CVS business is. McKesson's annual report for the year ended March 31, 2026 does. CVS was its largest customer and accounted for about 24% of total revenue of $403.43 billion. That works out to roughly $96.8 billion of sales to a single buyer.

• CVS made up about 21% of McKesson's trade accounts receivable at March 31.
• The next two customers were 11% and 10% of revenue, so the top three came to about 45%.
• The ten largest customers, including group purchasing organizations, were about 73% of revenue.
• The current agreement, last extended in fiscal 2023, runs to June 2027. The new one would add five years.

Drug distribution is a high-volume, thin-margin business. McKesson's gross margin for the year was 3.61%, so on revenue the size of the CVS account, every tenth of a percentage point of margin is worth about $97 million a year in gross profit. The release gives no pricing terms, and that is the figure investors will be looking for on the next call.

The thing the headlines skip: it is not signed yet

The release headline, and most coverage, say McKesson "extends" the deal. The body says "agreement in principle," and its own risk language spells out what that means: the definitive contract could be delayed by "protracted negotiations," the two sides "might fail to sign" it, and McKesson might not get all the benefits it expects. That is standard caution, but it is the difference between a done deal and a handshake on a contract this large.

Who it actually hits

For McKesson holders, a customer worth about a quarter of revenue was due to come off contract in June 2027, and this takes most of that renewal risk off the table if it is signed. For CVS, distribution is a cost line; its shares were slightly lower on the day.

What we're watching

McKesson said it will give more detail on its fiscal second-quarter earnings call on Nov. 4, 2026. The things to listen for are when the definitive contract is signed and whether the new terms change the margin on the account. Our stocks section tracks the rest of the day's company news.

Sources: McKesson press release (Business Wire, via BioSpace); McKesson fiscal 2026 Form 10-K on SEC EDGAR; Nasdaq market data; Investing.com. Dollar values of the CVS account and margin sensitivity are Chronicle calculations from the 10-K. This is market information, not investment advice.